The structurally unique amino-terminal domain of class II G protein-coupled receptors is critically important for ligand binding and receptor activation. Understanding the precise role it plays requires detailed insights into the molecular basis of its ligand interactions and the conformation of the ligand-receptor complex. In this work, we used two high-affinity, full-agonist, secretin-like photolabile probes having sites for covalent attachment in positions 21 and 23 and used sequential proteolysis and sequencing of the labeled region of the receptor to identify two new spatial approximation constraints. The position 21 probe labeled receptor residue Arg 15 , whereas the position 23 probe labeled receptor residue Arg 21 . A homology model of the amino-terminal domain of the secretin receptor was developed using the NMR structure of the analogous domain of the corticotropin-releasing factor receptor. This was attached to a homology model of the secretin receptor transmembrane bundle, with the two domains oriented relative to each other based on continuity of the peptide backbone and by imposing a distance restraint recently identified between the amino-terminal WDN sequence and the region of the helical bundle above transmembrane segment six. Secretin was docked to this model using seven sets of spatial approximation constraints identified in previous photoaffinity labeling studies. This model was found to fully accommodate all existing constraints, as well as the two new approximations identified in this work.
The secretin receptor is a prototypic member of the class II family of G protein-coupled receptors (GPCRs) that contains several potentially important drug targets, such as receptors for calcitonin, vasoactive intestinal polypeptide, glucagon, glucagon-like peptide, corticotropin-releasing factor (CRF), and parathyroid hormone (Ulrich et al., 1998) . Despite recent advances in the study of this receptor family, our understanding of receptor structure-function remains limited. Refinement of our understanding of the molecular basis of agonist ligand binding and activation of the secretin receptor should contribute insights relevant to the entire family and facilitate the design and refinement of potential receptoractive drugs.
Insights into mechanisms of agonist ligand binding and activation of the secretin receptor have come from natural ligand structure-activity relationships and from receptor mutagenesis and photoaffinity labeling studies (Gourlet et al., 1996; Dong et al., 2003) . These have identified the critical importance of the long and structurally complex amino terminus of this receptor for agonist ligand binding. This theme has been consistent for multiple other class II GPCR family members (Juppner et al., 1994; Cao et al., 1995; Gourlet et al., 1996) . Alignment of the receptor amino terminal sequences reveals conserved features, which include six cysteine residues with three intradomain disulfide bonds (Grauschopf et al., 2000; Lisenbee et al., 2005) . Insight into the structure of this region was substantially advanced with the solution of an NMR structure of the isolated amino terminus of the corticotropin-releasing factor (CRF2␤) receptor (Grace et al., 2004) . However, it remains unclear whether the amino terminus of the intact CRF receptor will have the same or related conformation, how similar the amino terminal region of other receptors in this family will be to that structure, or how ligands dock to these receptors.
Natural ligands for class II GPCRs are moderately long peptides (greater than 25 residues) having diffuse pharmacophoric domains (Ulrich et al., 1998) . Like natural ligands for other members of this family, the amino-terminal region of secretin contains key determinants for receptor selectivity and activation, whereas its carboxyl-terminal region contains determinants for high-affinity binding. Considerable experimental evidence indicates that the carboxyl-terminal regions of ligands for class II receptors interact with the aminoterminal regions of their receptors (Juppner et al., 1994; Gourlet et al., 1996; Pham et al., 2004; Tan et al., 2006) , whereas the amino terminus of the peptides is critical for agonist activity and interacts with parts of the receptor core and loop regions (Bisello et al., 1998; Dong et al., 2004) . Critical to understanding receptor activation is knowledge of how these ligands dock to their receptors. The most useful insights have come from intrinsic photoaffinity labeling studies that provide physical constraints on the relative position of peptide and receptor amino acids. The class II GPCR that has been most extensively studied this way is the secretin receptor, where spatial approximations have been established between residues scattered throughout the pharmacophore of secretin, in positions 6, 12, 13, 14, 18, 22, and 26 , and residues within the receptor amino terminus (Dong et al., 1999a (Dong et al., ,b, 2000 (Dong et al., , 2002 Zang et al., 2003) .
To date, the only photoaffinity labeling probes shown to covalently interact with receptor residues in regions other than the amino terminus are those having photolabile residues substituted into the amino-terminal end of the peptide ligand (Dong et al., 2004) . This type of observation, also reported for the parathyroid hormone receptor, has resulted in the hypothesis that natural peptide ligands of class II GPCRs can act as tethers interacting with both amino terminus and body of their receptors, exerting tension to induce the conformational change associated with activation and G protein association (Bisello et al., 1998) . We have proposed an alternative hypothesis (Dong et al., 2006 ) that describes a ligand-induced conformational change in the receptor amino terminus that exposes a previously "constrained" epitope (WDN in the secretin receptor) that can act as an endogenous agonist that interacts with and activates the body of the receptor.
Evaluation of these two apparently divergent activation mechanisms requires a more detailed understanding of the mechanism of binding and of the conformation of the complex between secretin and the amino terminus of the secretin receptor. We have therefore performed additional photoaffinity labeling experiments with new probes that incorporate photolabile residues into the important carboxyl-terminal region, in positions 21 or 23 of secretin. Both probes bound specifically and saturably to the secretin receptor and were full agonists. They were also able to covalently label single and distinct residues within the amino terminus of the receptor, at residues Arg 15 (for position 21 probe) and Arg 21 (for position 23 probe). We also have now used the NMR data for the amino-terminal domain of the structurally related CRF2␤ receptor (Grace et al., 2004) to refine that structure and to build a homology model of the analogous domain of the secretin receptor. We have oriented this relative to a homology model of the bovine rhodopsin helical bundle (Palczewski et al., 2000) to yield a preliminary full secretin receptor model. The previously identified spatial approximation constraints from photoaffinity labeling studies were used to provide initial ligand docking. This model was found to also nicely accommodate the two new spatial approximation constraints identified in the current work, with all of the currently available constraints contributing toward the most meaningful model of ligand docking yet proposed.
Materials and Methods
Materials. N-chlorobenzenesulfonamide (Iodobeads; a solid-phase oxidant), cyanogen bromide (CNBr), and m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester were purchased from Pierce Chemical Co. (Rockford, IL). Phenylmethylsulfonyl fluoride, 3-isobutyl-1-methylxanthine, and N-(2-aminoethyl-1)-3-aminopropyl glass beads were from Sigma (St. Louis, MO). Endoproteinase Lys-C and the 12CA5 monoclonal antibody that recognizes the hemagglutinin (HA) epitope were from Roche Applied Science (Indianapolis, IN). Secretin and endoglycosidase F were prepared in our laboratory, as described previously (Pearson et al., 1987 [Tyr 10 ]rat secretin, they incorporated a Tyr to replace Leu 10 , which has been shown to be well tolerated. Peptides were synthesized as described previously (Powers et al., 1988) , radioiodinated oxidatively using the solid-phase oxidant Iodobeads, and purified to homogeneity using reversed-phase high-performance liquid chromatography to yield specific radioactivities of 2000 Ci/mmol.
Receptor-Expressing Cell Lines. Several cell lines that had been established and well characterized previously were used as sources of receptor for this study. These included Chinese hamster ovary (CHO) cell lines stably expressing the wild-type secretin receptor (SecR) (Ulrich et al., 1993) , the HA-tagged wild-type secretin receptor (SecR-HA37) (Dong et al., 1999b) , and HA-tagged mutant secretin receptors (SecR-V16M-HA37 and SecR-V13M-HA37) (Dong et al., 2000) . Numbering of the residues in the secretin receptor reflects the cleavage of the 22-residue signal peptide sequence (Dong et al., 1999a) . These cell lines were cultured at 37°C in a 5% CO 2 environment on Falcon tissue culture plasticware in Ham's F-12 medium supplemented with 5% Fetal Clone-2 (HyClone Laboratories, Logan, UT). Cells were passaged twice a week and lifted mechanically before use. Plasma membranes were prepared using discontinuous sucrose gradient centrifugation (Hadac et al., 1996) . Membranes were then resuspended in Krebs-Ringers/HEPES (KRH) buffer containing 25 mM HEPES, pH 7.4, 104 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 0.01% soybean trypsin inhibitor, and 1 mM phenylmethylsulfonyl fluoride for storage at Ϫ80°C until they were to be used.
Binding Studies. Binding activities of the Bpa 21 and Bpa 23 probes were performed with enriched plasma membranes from the CHO-SecR cells in standard competition-binding assays, using conditions previously established (Hadac et al., 1996 in KRH buffer containing 0.2% bovine serum albumin for 1 h at room temperature (final volume, 500 l). Separation of bound from free radioligand was performed with a Skatron cell harvester (Molecular Devices, Sunnyvale, CA), using receptor-binding filter mats that had been presoaked in 0.3% Polybrene. Bound radioactivity was quantified using a gamma-spectrometer. Nonspecific binding was determined in the presence of 1 M unlabeled secretin and represented less than 15% of total binding. Data were graphed using Prism software (GraphPad Software, San Diego, CA) and were analyzed using the nonlinear least-squares curve-fitting routine in LIGAND (Munson and Rodbard, 1980) . Biological Activity Assay. Biological activities of the Bpa 21 and Bpa 23 probes were studied using assays for stimulation of intracellular cAMP in the receptor-bearing CHO-SecR cell line, as described previously (Ganguli et al., 1998) . CHO-SecR cells were incubated with increasing concentrations of the probe (0-1 M) for 30 min at 37°C in KRH buffer containing 0.2% bovine serum albumin, 0.01% soybean trypsin inhibitor, 0.1% bacitracin, and 1 mM 3-isobutyl-1-methylxanthine. Reactions were stopped by adding 6% (w/v) perchloric acid, and the pH was adjusted to 6.0 with 30% KHCO 3 . The cAMP concentrations in cell lysates were measured using a competitionbinding assay (Diagnostic Products Corporation, Los Angeles, CA) (Ganguli et al., 1998) . Radioactivity was quantified by scintillation counting in a Beckman LS6000 (Beckman Coulter, Fullerton, CA).
Photoaffinity Labeling. The detailed procedure has been described previously (Dong et al., 1999b) . Plasma membranes (ϳ50 g) were incubated with the 125 I-labeled Bpa 21 or Bpa 23 probes (ϳ0.1 nM) in KRH buffer for 1 h in the dark at room temperature in the presence of increasing concentrations of unlabeled secretin. The reaction was then exposed to photolysis for 30 min at 4°C using a Rayonet Photochemical Reactor (Southern New England Ultraviolet Co., Bradford, CT) equipped with 3500 Å lamps. Membranes were then washed with KRH buffer, solubilized in SDS sample buffer, and separated by gel electrophoresis on 10% SDS-polyacrylamide gels (Laemmli, 1970) . The apparent molecular masses of radiolabeled receptors, visualized by autoradiography, were determined by interpolation on a plot of the mobility of ProSieve protein standards (Lonza Rockland, Inc., Rockland, ME) versus the log values of their apparent masses.
Peptide Mapping. Photoaffinity-labeled secretin receptor was prepared in larger scale using ϳ200-g aliquots of plasma membranes and 0.5 nM 125 I-labeled Bpa 21 or Bpa 23 probes. Labeled bands were cut from gels, eluted, lyophilized, and precipitated with ethanol before subsequent cleavage. Purified labeled receptor was deglycosylated with endoglycosidase F and digested with CNBr and endoproteinase Lys-C under conditions described previously (Dong et al., 1999b) . Cleavage products were separated on 10% NuPAGE gels (Invitrogen, Carlsbad, CA) using MES running buffer. The apparent molecular masses of radiolabeled receptor fragments were determined by interpolation on a plot of the mobility of Multimark protein standards (Invitrogen) versus the log values of their apparent masses.
The identity of the affinity-labeled secretin receptor fragment resulting from CNBr cleavage was further established by immunoprecipitation with the 12CA5 anti-HA monoclonal antibody using the affinity-labeled HA-tagged receptor construct (SecR-HA37), previously shown to bind and signal identically to wild-type receptor (Dong et al., 1999b) . The immunoprecipitated material was eluted into sample buffer and resolved by NuPAGE gel electrophoresis.
Radiochemical Edman degradation sequencing (Dong et al., 1999b) was used to determine the specific sites of attachment after achieving definitive identification of the receptor fragments labeled with each probe. This involved the cross-linking of the receptor fragment of interest through cysteine residues to N-(2-aminoethyl-1)-3-aminopropyl glass beads. We used V13M-HA37 and V16M-HA37 mutant receptor constructs expressed in CHO cell lines for the Bpa 21 and Bpa 23 probes, respectively. Labeled receptor was purified and cleaved by CNBr and the resultant fragments were gel-purified to radioactive homogeneity before being covalently coupled through cysteine residues to maleimidobenzoyl succinimide-activated N-(2-aminoethyl-1)-3-aminopropyl glass beads. After this, repetitive cycles of manual Edman degradation were performed with quantitation of radioactivity released in each cycle. This procedure was repeated three times in independent experiments. Molecular Modeling. All molecular modeling activities were conducted using a stochastic global energy optimization procedure implemented in Internal Coordinate Mechanics (ICM) . This procedure consisted of the following iterative steps: 1) random conformational change of a dihedral angle according to the biased-probability Monte Carlo method ; 2) local minimization of all free dihedral angles; and 3) acceptance or rejection of the new conformation based on the Metropolis criterion at the simulation temperature, usually at 600 K (Metropolis et al., 1953) . This procedure can generate and search through diverse sets of conformations by actively sampling a selected set of dihedral angles. All calculations were carried out on computers equipped with 3.4-GHz Intel XEON-EMT processors.
Refinement of the NMR Models of the Mouse CRF2␤ Receptor Amino-Terminal Domain. The 20 NMR models of the mouse CRF2␤ receptor amino-terminal domain and the associated NMR distance restraints that were deposited into Protein Data Bank (PDB code 1U34) were obtained. The highly flexible regions at both ends of this domain were removed, retaining only residues 37 to 122. The models were then completed by attaching missing hydrogens, assigning ECEPP/3 atom types and charges (Nemethy et al., 1992) , followed by regularization to impose ideal covalent geometries on all bond angles and bond lengths. Eight hundred and three NMR restraints were converted to ICM-readable format and were imposed on the models using a quadratic restraint energy with a strength of 10 kcal/(mol Å 2 ) (Bordner and Abagyan, 2006) . Each of the 20 models was then subjected to local minimization, followed by 10 independent cycles of Monte Carlo sampling of both the backbone and side-chain dihedral angles at 600 K in ICM, each simulation lasting for more than 144 h (Abagyan and Totrov, 1999) . The lowest energy conformation for each of the 20 models was retained.
Homology Modeling of the Amino-Terminal Domain of the Rat Secretin Receptor. The multiple sequence alignment of class II GPCRs from the Swissprot database was used as a guide to align the sequence of the rat secretin receptor to the mouse CRF2␤ receptor amino-terminal domain (Boeckmann et al., 2003) . The 20 refined models of this domain of the CRF2␤ receptor were then used to generate 20 homology models of the amino terminus of the secretin receptor (Cardozo et al., 1995) . A subset of 115 NMR restraints of the CRF2␤ receptor amino terminus was imposed on the residues that are conserved between the secretin receptor and the CRF2␤ receptor. Each of the 20 models was then subjected to local minimization, followed by 10 independent cycles of Monte Carlo sampling of backbone and side-chain conformations at 600 K, each simulation lasting for more than 216 h. The lowest energy conformation for each of the 20 models was retained and further refined by Monte Carlo simulation at 100 K for 36 h.
Homology Modeling of the Transmembrane Domain of the Rat Secretin Receptor. The sequence of the transmembrane helices of the rat secretin receptor were aligned to those of bovine rhodopsin (PDB code 1U18) using the "cold spot" method (Frimurer and Bywater, 1999) . A homology model of the transmembrane helical bundle of the rat secretin receptor was then built in ICM. The packing of the model was further optimized by side-chain sampling and backbone minimization.
Alignment of the Amino-Terminal Domain of the Secretin Receptor with Its Transmembrane Helical Bundle. A distance restraint was imposed between the WDN epitope and the top of the sixth transmembrane segment. A second distance restraint was imposed between the carboxyl end of the amino-terminal domain and the amino-terminal end of helix 1. The amino-terminal domain was then docked onto the helical bundle by Monte Carlo sampling of the six positional variables of the amino-terminal domain. The contact between the two domains was further optimized by side chain sampling to generate a preliminary model of the secretin receptor incorporating both the amino terminus and receptor core (Ferná ndezRecio et al., 2003) .
Docking of Secretin to the Full Model of the Secretin Receptor. The initial conformation of secretin to be used in docking studies was taken from a previous solution-phase NMR determination of the porcine secretin structure (differs from the rat sequence only with a glutamine in position 14 in place of an arginine) (Clore et al., 1988 , and Leu 36 of the secretin receptor, respectively. Secretin was first docked to the grid potentials derived from the model of the intact secretin receptor in 10 independent runs. During the grid docking, the six positional variables of secretin were actively sampled, with rigid backbone and flexible side chain during local minimization cycles. All 10 independent runs converged to a single solution after 8 h of docking. Subsequently, the secretin/secretin receptor complex was refined. During refinement, the side chains of both secretin and the secretin receptor were actively sampled, while the backbone of secretin and residues 1 to 43 and 102 to 110 of the secretin receptor were allowed to be more flexible during cycles of local minimization. The refinement process typically lasted for 70 h, with the lowest energy conformation among the 10 independent runs retained. Finally, the two new residueresidue spatial approximation constraints determined by photoaffinity labeling in the current work were assessed in the model. The health of the models was established by PROCHECK and WHAT-_CHECK evaluations (Laskowski et al., 1993; Hooft et al., 1996) .
Results
Characterization of Photolabile Probes. Both the Bpa 21 and Bpa 23 probes were synthesized by manual solid phase techniques and purified by reversed-phase HPLC, and their identities were verified by mass spectrometry. They were functionally characterized in a competition radioligandbinding assay. As shown in Fig. 1 , both probes bound to the secretin receptor specifically and saturably, although with affinities lower than that of natural secretin (K i values: secretin, 2.7 Ϯ 0.1 nM; Bpa 21 probe, 17.9 Ϯ 1.2 nM; Bpa 23 probe, 47.1 Ϯ 14.2 nM). The probes were then tested for their ability to stimulate intracellular cAMP accumulation in CHO-SecR cells. As shown in Fig. 1 To gain insights into the domains of labeling by each of the probes, CNBr cleavage was first used. The secretin receptor contains nine Met residues and, in theory, CNBr cleavage would yield 10 fragments ranging in molecular mass from 1 to 11 kDa, three of which contain sites of glycosylation (Fig. 3) . As shown in Fig. 3 , CNBr cleavage of the secretin receptor labeled by each probe resulted in a fragment migrating at approximate M r ϭ 19,000 and shifting to M r ϭ 10,000 after deglycosylation. This pattern was the same for both probes, indicating that they might label the same region of the receptor. Based on the molecular masses of the attached probes (Bpa 21 probe, 3173 Da; Bpa 23 probe, 3216 Da) and on the glycosylated nature of the labeled bands, two fragments were felt to be candidates (segments including amino acid residues 1-51 and 74-123). Both of these fragments are within the amino-terminal tail of the secretin receptor, with one at the amino-terminal end of the receptor (fragment 1) and the other (fragment 3) adjacent to the first transmembrane segment (Fig. 3) . Previous experience with the electrophoretic migration of each of these CNBr fragments makes the first fragment most likely (Dong et al., 1999b; Zang et al., 2003) .
To definitively establish receptor residues 1 to 51 as the region of labeling, a well characterized receptor mutant that incorporates an HA epitope within this fragment (SecR-HA37) (Dong et al., 1999b) was used in immunoprecipitation experiments. Figure 4 shows that the M r ϭ 19,000 CNBr fragment radiolabeled by Bpa 21 and Bpa 23 probes was immunoprecipitated by the anti-HA monoclonal antibody and precipitation was prevented in the presence of excess HA peptide.
Endoproteinase Lys-C that cleaves at the carboxyl-terminal side of lysine residues was next used to further localize the region of covalent labeling by each probe. Figure 5 shows that endoproteinase Lys-C cleavage of labeled CNBr fragment 1 yielded a labeled fragment migrating at approximate M r ϭ 6000 that did not shift further after deglycosylation. This identified the nonglycosylated 30-residue fragment at the distal amino terminus of the secretin receptor as the domain of labeling by each of the probes. To further localize the region of labeling by each of the probes, two previously established secretin receptor mutant constructs, V13M-HA37 and V16M-HA37 (Dong et al., 2000) , were used. Both receptor mutants were specifically and saturably labeled with each probe (Fig. 6) (bottom) probes in the absence and presence of increasing concentrations of competing unlabeled secretin. The labeled secretin receptor with each probe migrated similarly at approximate M r ϭ 70,000 and shifted to approximate M r ϭ 42,000 after deglycosylation by endoglycosidase F (EF). Shown also are the densitometric analyses of three similar independent experiments by each probe, with data points expressed as means Ϯ S.E.M. No bands were detected in affinity-labeled nonreceptor-bearing CHO cell membranes. Fig. 3 . CNBr cleavage of the labeled secretin receptor. Left, shows a diagram of the predicted sites of CNBr cleavage of the rat secretin receptor, along with the masses of protein cores of these fragments. Residues are labeled sequentially from 1, after cleavage of the 22-residue signal peptide (Dong et al., 1999a) . Right, shows a representative autoradiograph of a 10% NuPAGE gel used to separate the products of CNBr cleavage of the secretin receptor labeled with the Bpa 21 and Bpa 23 probes. Cleavage of the native receptor labeled with each probe resulted in a band migrating at approximate M r ϭ 19,000 that shifted to M r ϭ 10,000 after deglycosylation with endoglycosidase F (EF). The best candidates representing this are the first fragment at the amino terminus of the receptor and the third fragment (bold circles).
Monte Carlo simulation (Table 1) . The results from PRO-CHECK show that after simulation, 25% more residues occupied the most favored regions, whereas the percentages of residues in the generously allowed and disallowed regions dropped from 11.6 and 3.3% to 1.9 and 1.0%, respectively. Likewise, results from WHAT_CHECK indicated significant improvement in quality of second generation packing, Ramachandran plot appearance, 1 / 2 rotamer normality, and backbone conformation after simulation. Nederveen et al. (2005) published the RECOORD database, in which more than 500 NMR models from the Protein Data Bank were recalculated. The largest improvement in the model quality was achieved by restrained molecular dynamics in a hydrated environment. Comparing their study with ours shows that refinement in ICM improved the model quality similar to that of Nederveen's study in all categories in PROCHECK and WHAT_CHECK, bringing the overall quality of the amino terminus of the CRF2␤ receptor to that of an average NMR model. Note that although the Z-score of the backbone conformation after refinement was still Ϫ8.4, it represented an improvement over the Z-score of the original models of Ϫ11.4. Consistent with this, Nederveen's refinement also did not improve the backbone conformations significantly.
To see how the refinement affected the overall structure of the models, we calculated the pairwise C ␣ root-mean-square deviation (rmsd) by superimposing the C ␣ of the stable central core residues 59 to 64, 70 to 81, and 100 to 113. For each of the 20 models, we superimposed the model before and after refinement; the resultant C ␣ rmsd for the central core and the remaining disordered region were 1.22 Ϯ 0.16 Å and 7.8 Ϯ 1.6 Å, respectively. These values reflected the degree of movement in the central core and the disordered region during refinement. As a reference, the pairwise C ␣ rmsd for the central core and the disordered region within the ensemble of the original 20 NMR models were 0.84 Ϯ 0.17 Å and 7.7 Ϯ 1.9 Å, respectively, which indicate the intrinsic flexibility/uncertainty in the two regions in the original NMR models. These results demonstrate that our simulation enables large movement in the disordered region while limiting the movement of the stable central core within experimental uncertainty, as shown in Fig. 8 .
Homology Modeling of the Amino Terminus of the Secretin Receptor. The aligned amino terminal regions of secretin and CRF2␤ receptors share 19% sequence identity and 36% sequence homology with the three disulfide bonds that are conserved throughout this family (Grace et al., 2004; Lisenbee et al., 2005) . An initial homology model of the amino terminus of the secretin receptor was produced using ICM, and was refined based on a subset of the original NMR distance restraints of the CRF2␤ receptor amino terminus that included 115 distance restraints between residues that are conserved among secretin and CRF2␤ receptors. The backbone and side-chain dihedral angles of the secretin receptor models were then sampled by biased-probability Monte Carlo method in the presence of these distance restraints. This refinement was necessary because of the low sequence identity and the highly undefined nature of the amino-terminal domain outside of its central core, as shown in the CRF2␤ receptor in Fig. 8 .
The ensemble of 20 rat secretin receptor amino terminus models after homology modeling and refinement is shown in Fig. 9 . We calculated the pairwise C ␣ rmsd within the ensemble by superimposing the C ␣ of the stable central core residues 43 to 48, 53 to 64, and 82 to 93. The C ␣ rmsd for the central core and the remaining disordered region were 2.11 Ϯ 0.60 Å and 11.3 Ϯ 2.0 Å, respectively. A comparison of these numbers with those of the original NMR models of the amino terminus of the CRF2␤ receptor (0.84 Ϯ 0.17 and 7.7 Ϯ 1.9 Å) shows a wider spread of the supposed stable central core, 
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probably reflecting the smaller number of distance restraints used in the modeling of this region of the secretin receptor. Only seven of the 20 models were found to contain an intact salt bridge between Asp 49 and Arg 83 , corresponding to the salt bridge between Asp 65 and Arg 101 proposed to be present in the amino terminus of the mouse CRF2␤ receptor. We inspected the distance restraints deposited in Protein Data Bank and found that there was no direct distance restraint connecting Asp 65 and Arg 101 in the original NMR models, even though this salt bridge was reported as a prominent feature of those conformations.
Molecular Model of the Intact Secretin Receptor. To study how secretin interacts with its receptor, we first constructed an initial model of the receptor including the receptor amino terminus and the seven-transmembrane segment bundle. A preliminary model of the transmembrane helical bundle domain was generated using a previously reported "cold-spot" method (Frimurer and Bywater, 1999) . We attached the seven secretin receptor amino-terminal domain models having an intact Asp 49 to Arg 83 salt bridge (that were most similar to the reported conformation of the CRF2␤ receptor) to this receptor transmembrane domain. The relative orientation of the two domains was restrained by the connection of the two domains at the amino-terminal end of helix 1 and by the proposed interaction between the WDN sequence and the transmembrane domain (Dong et al., 2006) . Seven models of the receptor that were consistent with these restraints were generated.
Secretin was first docked to the grid representation of the seven full models to maximize sampling efficiency. Because of the rigid nature of the receptor in grid docking, we subsequently carried out flexible backbone refinement. The C ␣ distances between cross-linked residues in secretin and the secretin receptor from photoaffinity labeling studies are shown for three of the best models in Table 2 . Note that the two photoaffinity labeling groups, p-benzoyl-L-phenylalanine and p-benzoylbenzoyl-L-lysine, can span distances of 10 and 15 Å, respectively. Therefore, the seven distance restraints between secretin and the amino-terminal domain of the secretin receptor coming from previous photoaffinity labeling studies were all satisfied.
Most importantly, the last two entries of Table 2 show that the two pairs of cross-linked residues being demonstrated for the first time in the current study (Arg 21 of secretin to receptor residue Arg 15 and Leu 23 of secretin to receptor residue Arg 21 ) were found to be within cross-linking distances in our models, even though these two sets of distance restraints had not been used during the peptide docking and refinement. Figure 10 shows the best working model for secretin docking to the receptor amino terminus and highlights the potential accessibility of the WDN sequence within the amino terminus of the receptor previously postulated as playing an endogenous agonist role by interacting with the body of the secretin receptor (Dong et al., 2006) . . Shown is one representative model.
Secretin Receptor Ligand Binding

Discussion
The molecular basis of natural peptide ligand binding to the amino-terminal domain of class II G protein-coupled receptors and the conformation of this domain are of substantial current interest. This is based on a series of observations showing that this region is key for agonist binding and receptor activation for multiple members of this family (Juppner et al., 1994; Cao et al., 1995; Gourlet et al., 1996) . The current work has focused on these aspects of the prototypic secretin receptor. This receptor was the first member of the class II GPCR family to be cloned and displays conservation of important domains in the natural peptide agonist ligand, as well as receptor structural signatures and functional mechanisms examined. This model system was chosen, because extensive experimental data are already available to facilitate the meaningful docking of secretin to this receptor.
Useful structural insights have come from the solution of the NMR structure of the amino-terminal domain of another class II GPCR, the CRF2␤ receptor (Grace et al., 2004 ). In the current work, we have carefully examined those reported structures and the distance constraints that had contributed to the reported models. In the current report, the CRF2␤ receptor model was refined, and the insights coming from it were applied to the analogous region of the structurally related secretin receptor. This probably represents a more meaningful template for a homology model for this region of the secretin receptor than the amino-terminal region of ribonuclease Mc1, which was previously used as template in the absence of the CRF2␤ receptor structure . Indeed, the core regions of the amino-terminal structures of the secretin receptor and of the CRF2␤ receptor have now been found to be very similar.
Most of the experimentally defined sites of residue-residue approximation that have been determined for the secretin receptor are within the first 38 residues of the distal amino terminus in poorly constrained regions of this structure. Of particular interest is that the regions of the secretin receptor that are homologous to the relatively stable core of the amino terminus of the CRF2␤ receptor have not been covalently labeled by any of positions of photolabile residues spread throughout the pharmacophoric domain of secretin receptor probes that have been used to date. This raises the possibility that this stable core provides a lattice deep in the structure with the portions of the receptor that interact with the natural peptide ligands situated above it.
Although placement of the peptide ligands within the amino-terminal domain is crucial to understanding high-affinity binding for class II receptors, an additional key factor to resolving the mechanism of receptor activation by agonists is the positioning of both the peptide ligand and receptor amino-terminal domain relative to the heptahelical transmembrane core.
There are currently few empirical data to direct the organization of the receptor amino-terminal domain and the transmembrane receptor core, and this has led to disparate models of the relative positioning of these two domains. For Fig. 10 . Refined conformation of the amino terminus of the secretin receptor. This structure accommodates nine photoaffinity labeling constraints and the three disulfide bonds shown to exist in the secretin receptor (model 1 from Table 2 ). It also demonstrates the potential availability of the WDN sequence (highlighted) as a possible endogenous agonist ligand that could interact with the body of the secretin receptor. This is illustrated two different ways: the left panel illustrates the entire sequence; the right panel removes the distal ends of the receptor amino terminus to highlight the peptide-binding surface. Left, the amino-terminal domain is represented in yellow, the transmembrane domain in gray. The secretin peptide is colored blue-red from the amino terminus to the carboxyl terminus. The WDN motif and the three solvent accessible, glycosylated Asn 78 , Asn 84 , and Asn the CRF2␤ receptor, the orientation used was based on a proposed interaction between a negatively charged surface of the receptor amino-terminal domain and positively charged residues present in the extracellular loops of the receptor core (Grace et al., 2004) , whereas the VPAC1 receptor aminoterminal domain was arbitrarily placed above the receptor core in the recently proposed model of the intact VPAC1 receptor (Tan et al., 2006) . In both cases, the docking of peptides to their receptors relied significantly on general consideration of the functional roles of the amino-and carboxyl-terminal ends of the peptide ligands across class II receptors that are dependent upon the orientation of the receptor amino-terminal domain and receptor core. These models are further complicated by lack of direct knowledge of regions of the amino terminus that are disordered in the NMR structure that form the basis for receptor amino-terminal domain modeling.
In the current report, we have used two restraints in determining how to best position the amino-terminal domain of the secretin receptor with its helical bundle domain. The first restraint is the integrity of the peptide backbone involved in connecting the two domains, bringing the amino-terminal end of the first transmembrane helix to the carboxyl-terminal end of the receptor amino terminus. This is a common feature of each of the receptor models; however, the innate flexibility of the distal end of the receptor amino-terminal domain allows multiple surfaces to potentially abut the receptor core. The second restraint is specific to the secretin receptor and assumes that the WDN sequence within the amino terminus of the receptor interacts with the helical bundle above transmembrane segment six (Dong et al., 2006) . This was based on a series of studies demonstrating the ability of this receptor sequence to act as an endogenous agonist ligand, with its site of interaction demonstrated by covalent labeling of the receptor body using two distinct photoaffinity labeling probes derived from the critical WDN tripeptide (Dong et al., 2006) . It is noteworthy that similar activation of VPAC1 and calcitonin receptors by homologous endogenous peptide sequences has also been shown to occur, suggesting that such activation may be a common mechanism within the class II GPCR family (Dong et al., 2006) .
Secretin was docked to this preliminary model of the secretin receptor using the seven published photoaffinity labeling spatial approximation constraints. Of particular interest is that, with the peptide docked this way and given the proposed orientation of the two domains of the secretin receptor, the amino terminus of the peptide was found to be adjacent to the helical bundle in the region it has been independently shown to photoaffinity label (Dong et al., 2004) . In addition, the two spatial approximation constraints newly identified in the current report were also compatible with this docking and orientation. It is encouraging that these independently derived observations are fully compatible with the working model.
Critical comparison of the currently proposed model of the mode of peptide docking to the amino-terminal domain of the secretin receptor with those of the astressin/CRF-occupied CRF2␤ receptor (Grace et al., 2004) and of the vasoactive intestinal polypeptide-occupied VPAC1 receptor (Tan et al., 2006) , shows clear differences. As discussed above, the orientations of the amino-terminal domains with the helical bundle domains of these receptors are all different. The secretin receptor orientation was guided by the WDN motif and was, therefore, fully consistent with its interaction with the relevant region of the receptor body. However, in the CRF2␤ receptor model, the amino-terminal domain interacts with the transmembrane domain through the "back side" of the model displayed in Figs. 8 and 9 . As a consequence, Leumains to be explored. It should be noted, however, that there is no explicit salt-bridge present from the CRF2␤ NMR distance restraints, whereas mutation of Asp 49 to glycine has no negative effect on the biological activity of the secretin receptor (Dong et al., 2006) . It is also recognized that solventaccessible salt bridges are easily broken. Such a breakable salt-bridge between Asp 49 and Arg 83 of the secretin receptor is still consistent with the endogenous agonist hypothesis (Dong et al., 2006) . However, in the best conformation of the secretin-occupied secretin receptor currently being proposed, the WDN motif is readily accessible to its proposed target of action, even with the salt-bridge incorporated.
It is encouraging that, in the current work, multiple experimentally derived residue-residue distance constraints were easily accommodated within the molecular model of the secretin receptor. With initial peptide docking accomplished based on the previously described seven constraints, it was even more encouraging that the currently derived two additional constraints were also then well accommodated. In the best working model, all existing experimentally derived constraints were fully accommodated, and the WDN motif was available for interaction with the body of the receptor.
